Breaking News, Collaborations & Alliances

Crown Bioscience Opens Singapore Lab, Partners with JSR Life Sciences

The new facility will offer a broad portfolio of high-demand cell line-derived xenograft (CDX) and syngeneic models.

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences, opened a new site in Singapore to expand the company’s capacity to support both global and local biotech and pharma companies engaged in preclinical and translational oncology drug discovery and development.

The new facility will initially offer a broad portfolio of high-demand cell line-derived xenograft (CDX) and syngeneic models, alongside supporting analytical biomarker capabilities including flow cytometry and pathology services.

The company is also collaborating with the established biomedical community in Singapore to bring not only the foundational capabilities of Crown Bioscience’s preclinical services to Singapore but also novel technologies and services.

To support the growth goals for the Singapore site, and with a particular focus on the burgeoning local biotech industry, Crown Bioscience has entered into a distribution agreement with Biosys Corporation Pte Ltd., a specialized commercial partner with unique contacts within the Singaporean life sciences ecosystem.

Keefe Chng, executive director, and general manager of the Singapore facility said: “We are extremely excited to join the local biomedical community. Our core capabilities and experience will help the booming local biotech industry advance their preclinical and translational studies, while at the same time enable Crown Bioscience to bring unique high-end technologies to our global partners.”

Ivan Fu, Director of Biosys Corporation, said: “We believe that Crown Bioscience’s new facility in Singapore will inject a new standard for quality and innovation in the local preclinical market. As a distributor of Crown Bioscience in Singapore, our aim is to accelerate our customers research to improve the future of cancer treatment.”

In 2022 the company announced a joint venture launch with sister company MBL in Japan, alongside facility expansions and upgrades to the company’s Chinese presence.

In addition, the investments coincide with the fast-growing biotechnology sector across the region, while recognizing the importance of local understanding and language in support of the company’s client base.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters